A number of investment brokers have recently updated their price targets on shares of Catabasis Pharmaceuticals, Inc. (CATB). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

03/28/2016 – Catabasis Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 27 price target on the stock.

03/22/2016 – Catabasis Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Citigroup. They now have a USD 16 price target on the stock.

07/20/2015 – Oppenheimer began new coverage on Catabasis Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 28 price target on the stock.

07/20/2015 – Cowen began new coverage on Catabasis Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 30 price target on the stock.

The share price of Catabasis Pharmaceuticals, Inc. (CATB) was up +5.87% during the last day of trading, with a day high of 4.40. 19107 shares were traded during the last session.

The stock’s 50 day moving average is 5.00 and its 200 day moving average is 6.43. The stock’s market capitalization is 66.24M. Catabasis Pharmaceuticals, Inc. has a 52-week low of 3.90 and a 52-week high of 16.96.

View other investors thoughts on Catabasis Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.